In glioma patients, fibrinogen-like protein 2 (FGL2) produced by cancer cells interacts with the GM-SCF signaling, which influences differentiation of CD103+cDC1s and limits CD8+ T cells immune response. This evidence concerns the gene CD8A and cancer.